Cholesterol paradox: a correlate does not a surrogate make

Area of Science:

• Cardiology
• Metabolic Diseases
• Clinical Trials

Background:

• The global strategy to lower cholesterol via diet and medication has not effectively reduced the rising rates of coronary heart disease worldwide.
• While some attribute this failure to increasing obesity and diabetes, an alternative explanation is the potential inaccuracy of the cholesterol hypothesis itself.

Purpose of the Study:

• To critically review the evidence challenging the cholesterol hypothesis.
• To examine the implications of recent clinical trial data, such as the ACCELERATE trial, on the validity of targeting cholesterol for cardiovascular disease prevention.

Main Methods:

• Review of existing scientific literature and clinical trial data.
• Analysis of the ACCELERATE trial results concerning evacetrapib's effect on lipid levels and cardiovascular outcomes.
• Perspective piece synthesizing evidence that questions the cholesterol hypothesis.

Main Results:

• The ACCELERATE trial showed no cardiovascular benefit from evacetrapib, despite significant alterations in low-density lipoprotein cholesterol and high-density lipoprotein cholesterol levels.
• This trial adds to a body of evidence that casts doubt on the cholesterol hypothesis and the use of cholesterol as a surrogate endpoint.
• The focus on cholesterol may have inadvertently contributed to the cardiovascular disease pandemic.

Conclusions:

• The cholesterol hypothesis, which links lower cholesterol to reduced cardiovascular disease, faces significant challenges from recent data.
• The utility of cholesterol levels as a surrogate endpoint for cardiovascular risk is questionable.
• There is a need to re-evaluate current strategies for preventing coronary heart disease in light of contradictory evidence.